Quotables
"The Americans have need of the telephone, but we do not. We have plenty of messenger boys."
Sir William Preece, chief engineer, British Post Office ; 1878
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129879 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, th... | 05/24/2012 |
| 20120107400 | SUSTAINED RELEASE COMPOSITION OF THERAPUTIC AGENT A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent ... | 05/03/2012 |
| 20120108621 | PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.... | 05/03/2012 |
| 20120108622 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in ... | 05/03/2012 |
| 20120107250 | ABUSE-PROOFED DOSAGE FORM An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at l... | 05/03/2012 |
| 20120083505 | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states The present invention is directed to an opioid receptor antagonist or a pharmaceutically acceptable salt thereof for use in a method of acute treatment of paraphilic sexual arousal states in patients suffering from paraphilia.... | 04/05/2012 |
| 20120083506 | REDUCTION OF OPIOID BLOOD FLUCTUATIONS The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.... | 04/05/2012 |
| 20120082718 | Morphine Formulations Described is a pellet composition comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a coatin... | 04/05/2012 |
| 20120070495 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.... | 03/22/2012 |
| 20120045506 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profil... | 02/23/2012 |
| 20120046272 | Novel Therapeutic Compounds The present invention describes a series of therapeutically active compounds of formula I,
that are useful for treating a disorder in a mammal. In the f... | 02/23/2012 |
| 20120040009 | PARTICULATE PHARMACEUTICAL COMPOSITION WITH AN OPIOID AND AN OPIOID ANTAGONIST The invention relates to a pharmaceutical composition comprising first particles and second particles, the first particles comprising at least one opioid or a pharmaceutically acceptable salt thereof, and the second particles comprising at least one opioid antagonist or... | 02/16/2012 |
| 20120039957 | OPTIMIZED NIACIN COMPOSITIONS IN PHARMACEUTICAL PRODUCTS The present invention includes compositions and methods related to forms of niacin with enhanced in-vivo absorption and bioavailability. Such enhanced delivery of niacin in the presence of food may be achieved by size reduction of crystalline niacin, use of amorphous fo... | 02/16/2012 |
| 20120039962 | Pharmaceutical Compositions Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat... | 02/16/2012 |
| 20120041014 | Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may c... | 02/16/2012 |
| 20120034171 | ABUSE-PROOFED DOSAGE FORM The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that cou... | 02/09/2012 |
| 20120034306 | POLYMERIC DRUG DELIVERY SYSTEMS AND PROCESSES FOR PRODUCING SUCH SYSTEMS The subject invention relates to implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants.... | 02/09/2012 |
| 20120029008 | CRYSTALLINE AND AMORPHOUS FORMS OF NALBUPHINE HYDROCHLORIDE The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.... | 02/02/2012 |
| 20120029007 | MORPHINAN COMPOUNDS This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are ... | 02/02/2012 |
| 20120028960 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected fr... | 02/02/2012 |
| 20120018333 | Reducing Side Effects of Tramadol The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The ... | 01/26/2012 |
| 20120022093 | CRYSTALLINE FORMS OF OXYMORPHONE HYDROCHLORIDE The present invention is directed to crystalline forms of oxymorphone hydrochloride.... | 01/26/2012 |
| 20120015031 | NOVEL GASTRO-RETENTIVE DOSAGE FORMS A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least one pharmaceutically acceptable excipient, which dosage form is retained ... | 01/19/2012 |
| 20120009261 | NOVEL GASTRO-RETENTIVE DOSAGE FORMS A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours a... | 01/12/2012 |
| 20120010232 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (M... | 01/12/2012 |
| 20110318345 | NASAL DELIVERY substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nas... | 12/29/2011 |
| 20110318392 | DRUG COATING PROVIDING HIGH DRUG LOADING AND METHODS FOR PROVIDING THE SAME The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug,... | 12/29/2011 |
| 20110318321 | CONTROLLED RELEASE PHARMACEUTICAL OR FOOD FORMULATION AND PROCESS FOR ITS PREPARATION The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also ... | 12/29/2011 |
| 20110312911 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... | 12/22/2011 |
| 20110311631 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING A POLYMER MIXTURE AND EXCIPIENTS The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profil... | 12/22/2011 |
| 20110306603 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.... | 12/15/2011 |
| 20110306628 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is invol... | 12/15/2011 |
| 20110306627 | Morphinan Compounds This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods... | 12/15/2011 |
| 20110301131 | Drug Delivery Implants and Processes for Their Preparation The invention discloses an implant suitable for delivery of at least one drug, the implant comprising a fibrillar collagen matrix having, as measured in Example 1, a viscosity of greater than 100 mPas, optionally greater than 103 mPas, further optionally greater than 10... | 12/08/2011 |
| 20110301082 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... | 12/08/2011 |
| 20110300217 | HYDROMORPHONE THERAPY A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.... | 12/08/2011 |
| 20110293716 | PHARMACEUTICAL FORMULATION CONTAINING IBUPROFEN AND CODEINE The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elemen... | 12/01/2011 |
| 20110294843 | ADMINISTRATION SCHEME OF POLAR OPIOID METABOLITES FOR POST-OPERATIVE PAIN MANAGEMENT Administration scheme of an analgesically active polar metabolite of an opioid or the salt thereof for the manufacture of a medicament for the treatment of pain after medical operation, whereas the medicament is administered at least once before the end of the medical o... | 12/01/2011 |
| 20110288113 | METHOD TO REDUCE OR ELMINATE THE USE BY A PATIENT OF A TOLERANCE-INDUCING PHARAMACOLOGICAL AGENT A multiple total daily dose regimen is developed in order to decrease the use by a patient of a tolerance-inducing pharmacological agent. In one example, the method reduces or phases out altogether a patient's chronic use of opioid drugs by use of a successive reduction... | 11/24/2011 |
| 20110288079 | Tannate Compositions, Methods of Making and Methods of Use Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.... | 11/24/2011 |
